Demand for GLP-1 receptor agonists continues to outpace pharmaceutical manufacturing capacity. The supply bottleneck has prompted unprecedented capital allocation toward sterile fill-finish operations and active ingredient synthesis.
Broader Market Implications
Health insurance providers are renegotiating coverage terms, demanding long-term outcome data before approving expanded indications. Concurrently, medical device makers report shifting trends in elective surgical volumes.